Articles

ACC.21: There was no difference found between high- and low-dose aspirin in terms of effectiveness and safety in patients with established CVD, according to new research. 

ACC.21: High- and Low-Dose Aspirin Both Effective for Patients with Established Cardiovascular Disease

ACC.21: Black patients from disadvantaged neighborhoods were found almost 20%  more likely to die within 5 years of MI than white patients from well-resourced ones in a new study. 

ACC.21: Survival After MI Far Worse for Black Patients from Disadvantaged Neighborhoods  

ACC.21: Findings from a study released in advance of the ACC annual meeting suggest that prediabetes confers nearly twice the risk of major cardiovascular events vs normoglycemia.  

ACC.21: Prediabetes Significantly Increases Risk for MACE, According to New Findings 

ACC.21: High rates of obesity, hypertension, and hyperlipidemia found in Black women in their 20s and 30s are of significant concern, says the author of a study to be presented at the ACC meeting. 

Black Women at Risk Early in Life for Future Cardiovascular Disease  

Exercising at least 4 times a week can increase left ventricular mass and preserve elasticity, thereby reducing the risk of diastolic heart failure. Researchers from Texas presented their study results at the American College of Cardiology’s 60th Annual Scientific Session.

Regular Exercise in Middle Age Can Build Heart Muscle

Measurement of pulse pressure may help identify patients with "white coat" hypertension, according to data presented by Korean researchers at the American College of Cardiology’s 60th Annual Scientific Session.

Pulse Pressure May Be Clue to White Coat Hypertension

What is the optimal duration for antiplatelet therapy after placement of drug-eluting stents? Initial results of the EXCELLENT study show that 6 months of antiplatelet therapy is as effective as the 12-month regimen recommended by current guidelines.

Shorter Antiplatelet Regimen Sufficient After Stenting

A Danish study found no clinical benefit from using NT-proBNP (b-type natriuretic peptide) to identify and monitor high-risk patients with chronic heart failure, according to research from the NorthStar study presented at the American College of Cardiology’s 60th Annual Scientific Session in New Orleans.

Chronic Heart Failure Outcomes Not Improved by NT-proBNP-Guided Treatment

Compared with medical therapy alone, coronary artery bypass grafting (CABG) significantly reduced cardiovascular deaths and the composite end point of all-cause deaths and cardiovascular-related hospitalizations, reported investigators from the Surgical Treatment of Ischemic Heart Failure (STICH) trial. However, the effect of the two management strategies on overall survival in patients with ischemic heart failure was similar.

CABG Bests Medical Therapy in Ischemic Heart Failure

Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) released a focused update to the 2007 guidelines for the management of patients with unstable angina (UA)/non-ST-elevation myocardial infarction (non-STEMI).